AngioJet Rheolytic Thrombectomy Combined with Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction: An Observational Study
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261439485 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 08.06.2026. Verfasst von Yi-Xiong Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Haidian District, Peking, 100853, People's Republic of China. Hauptthemen laut MEDLINE: Thrombectomy, Platelet Glycoprotein GPIIb-IIIa Complex, Myocardial Infarction, Platelet Aggregation Inhibitors. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the efficacy and safety of AngioJet rheolytic thrombectomy with the adjunctive use of glycoprotein IIb/IIIa inhibitors (GPI) in the setting of ST-segment elevation myocardial infarction (STEMI).
Methods
We conducted a retrospective cohort study of 877 consecutive patients with STEMI. Propensity score matching (PSM) was employed to balance the baseline characteristics between the group receiving AngioJet rheolytic thrombectomy plus GPI (the AT + GPI group) and those receiving routine treatment (the RT group). The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE) at 1 year. Safety endpoints comprised any bleeding and major bleeding events.
Results
Ninety-seven patients received AngioJet rheolytic thrombectomy and GPI. No significant differences were observed between the two groups regarding in-hospital mortality, reinfarction, stent thrombosis, stroke, or bleeding. After propensity-score matching, the cumulative incidence of MACCE at 1 year did not differ significantly between the AT + GPI group and the RT group (8.2% vs 9.3%; hazard ratio, 0.894; 95% CI, 0.345 to 2.318; p = 0.818). The incidence rates of all individual safety endpoints—including stroke and bleeding—showed no significant differences between the two groups.
Conclusions
In this observational cohort of STEMI patients, the strategy of combining AngioJet rheolytic thrombectomy with GPI was not associated with improved 1-year outcomes compared to routine treatment, though it did not increase bleeding or stroke risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School of Chinese People's Liberation Army General Hospital, 28 Fuxing Road, Haidian District, Peking, 100853, People's Republic of China.
- Department of Cardiology, Sixth Medical Center of Chinese People's Liberation Army General Hospital, 6 Fucheng Road, Haidian District, Peking, Beijing, 100048, People's Republic of China.
ORCID-Profile: Yi-Xiong Huang
Zitieren
APA
Huang, Y. X., Cao, Y., Chen, Y., Qiu, Y. G., Liu, Y. M., He, J. C., Zhao, L., & Xu, Y. (2026). AngioJet Rheolytic Thrombectomy Combined with Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction: An Observational Study. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261439485
Vancouver
Huang YX, Cao Y, Chen Y, Qiu YG, Liu YM, He JC, et al. AngioJet Rheolytic Thrombectomy Combined with Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction: An Observational Study. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261439485
BibTeX
@article{Huang2026,
author = {Huang, Yi-Xiong and Cao, Yi and Chen, Yu and Qiu, Yi-Gang and Liu, Ying-Ming and He, Jiang-Chun and Zhao, Li and Xu, Yong},
title = {AngioJet Rheolytic Thrombectomy Combined with Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction: An Observational Study},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261439485}
}
EUVIMED